[Time course of bioelectrical activity of retina in patients with pigmented abiotrophy treated by deoxinate].
Bioelectrical retinal activity was assessed before and after a course of deoxinate therapy and in a blind placebo test in order to assess the efficacy of this new drug in the treatment of patients with pigmented retinal abiotrophy. Time course of electroretinograms during deoxinate therapy indicated a significant positive effect of the drug on retinal function as regards a variety of electrophysiological parameters in 80-94% patients. Improvement of electroretinography data was paralleled by improvement of visual acuity, extension of visual fields, and decrease of scotomas. Good effect was attained in patients with early and far advanced stages of pigmented retinal abiotrophy. Analysis of bioelectrical activity of the retina after a course of therapy with deoxinate and enkad showed a higher efficacy of the former drug in patients with pigmented retinal abiotrophy.
Tsapenko
I V
IV
Riabina
M V
MV
Zueva
M V
MV
Eliseeva
R F
RF
Katsnel'son
L A
LA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D004247:DNA / Q000627:therapeutic use*; D004311:Double-Blind Method; D004596:Electroretinography / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D009843:Oligoribonucleotides / Q000008:administration & dosage; D012160:Retina / Q000187:drug effects / Q000503:physiopathology*; D012174:Retinitis Pigmentosa / Q000188:drug therapy* / Q000503:physiopathology; D012265:Ribonucleotides / Q000008:administration & dosage; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D009843:Oligoribonucleotides; D012265:Ribonucleotides; C031373:ENKAD; D004247:DNA